A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.

Stephen W BoothToby A EyreJohn WhittakerLeticia CampoLai Mun WangElizabeth SoilleuxDaniel RoystonGabrielle ReesMurali KesavanCatherine HildyardFarasat KazmiNick La ThangueDavid KerrMark R MiddletonGraham P Collins

Published in: BMC cancer (2021)

ClinicalTrials.gov identifier NCT01977638 . Registered 07 November 2013.

Keyphrases

papillary thyroid
diffuse large b cell lymphoma
open label
randomized controlled trial
placebo controlled